Trial Profile

Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Oct 2024 Status changed from recruiting to active, no longer recruiting.
16 Oct 2024 Planned primary completion date changed from 1 Sep 2024 to 1 May 2025.
09 Sep 2024 According to a NiKang Therapeutics media release, company announced that preliminary data from this study will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) 2024 Congress on September 13, 2024, in Barcelona, Spain.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com